Ciurea Stefan O, Sadegi Barry, Wilbur Andrew, Alagiozian-Angelova Victoria, Gaitonde Sujata, Dobogai Lisa C, Akard Luke P, Hoffman Ronald, Rondelli Damiano
Department of Medicine, Division of Hematology, University of Illinois at Chicago College of Medicine, Chicago, IL 60612, USA.
Br J Haematol. 2008 Apr;141(1):80-3. doi: 10.1111/j.1365-2141.2008.07010.x.
Changes in spleen size postallogeneic haematopoietic stem cell transplantation (HSCT) in patients with primary myelofibrosis have been poorly characterized. We analysed 10 patients with myelofibrosis and splenomegaly following a reduced-intensity allogeneic HSCT. All patients fully engrafted donor cells including five patients with extensive splenomegaly. Extensive splenomegaly was associated with a prolonged time to neutrophil and platelet recovery. In all 10 patients, a progressive reduction of splenomegaly was documented within 12 months post-transplant and paralleled the reduction of marrow fibrosis. These findings suggest that myelofibrosis patients with extensive splenomegaly may proceed with allogeneic HSCT without prior splenectomy.
原发性骨髓纤维化患者接受异基因造血干细胞移植（HSCT）后脾脏大小的变化特征尚不明确。我们分析了10例接受减低强度异基因HSCT后出现骨髓纤维化和脾肿大的患者。所有患者均实现供体细胞完全植入，其中5例患者存在广泛脾肿大。广泛脾肿大与中性粒细胞和血小板恢复时间延长相关。在所有10例患者中，移植后12个月内均记录到脾肿大逐渐减轻，且与骨髓纤维化减轻情况平行。这些发现表明，存在广泛脾肿大的骨髓纤维化患者在未预先进行脾切除的情况下也可进行异基因HSCT。
